The "Assisted Reproductive Code" Behind the Greater Bay Area: JXR (01951) Seizes the Opportunity to Cultivate the First "Ten Thousand Cycle" Super Leader

In recent years, as connections between cities have become increasingly tight, the flow of talent, capital, and medical resources has accelerated. The previously dispersed reproductive health needs across different cities are gradually concentrating in the Guangdong-Hong Kong-Macao Greater Bay Area, a large interconnected regional market with a population exceeding 88 million and an economic total of over 15 trillion yuan. Notably, within the Greater Bay Area, Guangdong Province has maintained the highest birth rate in the country for eight consecutive years. Since 2018, more than 10% of the country's newborns have come from Guangdong Province each year, and by 2025, the number of newborns from Guangdong is expected to account for approximately 13% of the national total, providing unique population dynamics for the Greater Bay Area. The high birth rate is supported by the strong momentum created by the young population structure in Guangdong and the continuous influx of young people. Data shows that nearly 70% of Guangdong's population is of working age, and the sustained influx of young people injects lasting reproductive momentum into the Greater Bay Area, creating ample space for the improvement of assisted reproductive technology penetration in the region. However, as one of the countrys most significant areas for densely concentrated reproductive services, the level of assisted reproductive service concentration within the Greater Bay Area remains relatively low. Data indicate that there are over 60 reproductive centers in Guangdong Province alone, with approximately 110,000 assisted reproductive treatment cycles conducted each year. Yet, as of now, a super fertility center capable of achieving an annual treatment cycle volume exceeding 10,000 and demonstrating sustainable growth has yet to emerge, indicating a significant market gap that needs to be addressed. Against this backdrop, JXR (01951), the largest assisted reproductive medical institution in the country, is establishing a layout of "one hospital and two centers" through the Shenzhen Zhongshan Maternity and Child Health Hospital, Hong Kong Gratitude Medical Center, and Jinxin Medical Technology Innovation Center, with its southern headquarters located in Shenzhen. This initiative is expected to further integrate the service and research advantages of the Greater Bay Area and introduce leading industry technologies, academic resources, and management practices from Southeast Asia, Europe, and the United States, constructing a super assisted reproductive medical hub that serves the Greater Bay Area while radiating to Southeast Asia and the international market. China boasts the largest potential population for assisted reproduction, yet it lacks benchmark reproductive centers. The "2026 White Paper on the Development Status and Future Trends of China's Assisted Reproductive Industry" indicates that from 2020 to 2030, driven by the rising proportion of infertility due to advanced age and improved treatment penetration rates, China's assisted reproductive market is currently in a phase of demand release, with market size growing against the demographic cycle, expected to increase from 23.5 billion yuan to 63 billion yuan. Fueled by improvements in the macro environment, released delayed demands, and expanded medical insurance coverage, the period between 2026 and 2027 is expected to be a critical turning point for the transition of China's assisted reproductive industry from an adjustment phase to a recovery phase. With the concentrated release of industry demand, the number of oocyte retrieval cycles in the country is also steadily increasing: projected to exceed one million cases by 2025 and reach 1.885 million cases by 2035, with an average annual compound growth rate of over 7%. As mentioned above, the reason the Greater Bay Area is becoming one of the most significant high-density reproductive supply areas in the country is largely due to the strong momentum provided by Guangdong's youthful population structure and ongoing influx of young individuals. Within Guangdong Province, Shenzhen, where JXR's southern headquarters is located, serves as a key point for population movement and reproduction. Data indicates that by the end of 2024, Shenzhens resident population will be approximately 17.99 million, with an average age of 32.5 years. Those aged 15 to 59 comprise nearly 80% of the population, with youth aged 14 to 35 making up almost half, making it a bona fide "city of youth". The per capita disposable income of residents has reached 81,100 yuan. The youth demographic, robust purchasing power, and continuously improving payment guarantees form the foundation for the development of reproductive health services. The payment policy is the second key variable in the Greater Bay Area. Taking Shenzhen as an example, according to disclosures from the Shenzhen Medical Insurance Bureau, from October 1, 2024, eight assisted reproductive proceduresincluding oocyte retrieval, embryo culture, embryo transfer, and intracytoplasmic sperm injectionwill be covered by basic medical insurance, with first-class outpatient treatments applied and no payment threshold set, allowing for reimbursement of up to 90%. In the year following the policy's implementation, over 37,000 families in Shenzhen received support, with insurance funds exceeding 241 million yuan. The lowering of payment thresholds is enabling more potential demand to enter standardized treatment earlier. This means that not only is there dense demand within the Greater Bay Area, but a regionally supported center of payment is also forming. In addition, the Greater Bay Area serves as a natural hub for cross-border patients. The Greater Bay Area has significant advantages in cross-border assisted reproductive services: short physical distances, low communication costs in terms of language and culture, and significantly lower time costs for travel within the Guangdong-Hong Kong-Macao region compared to overseas medical treatment; a high density of supply within the Greater Bay Area, with leading centers managing complex cases efficiently; and a rapid pace of actions regarding medical insurance policies, medical management, lab expansion, and service chain design in the three regions, especially fitting for frequent follow-up patients. Amid the changes in population structure, improvements in fertility support policies, and continuous advancements in assisted reproductive technology, the Chinese assisted reproductive industry remains in a long-term development phase. In this context, the Guangdong-Hong Kong-Macao Greater Bay Area, benefiting from demand density, payment policies, and cross-border acceptance capacity, is expected to become an important template for establishing a fertility-friendly society in the country and act as a bridgehead for the development of assisted reproduction. The national drive towards a "fertility-friendly" society is bolstered by measures aimed at reducing patient burdens in accessing healthcare, creating a supportive social environment, and promoting a friendly understanding of assisted reproductive technologies, all of which the Greater Bay Area is leading across the country, providing fertile ground for assisted reproductive medical institutions. In terms of lowering patient medical expenses, Guangdong's medical insurance support for assisted reproduction is leading nationwide. (Supplemental medical insurance support policies). At this year's European Reproductive Conference, a set of data indicated that if patient out-of-pocket costs are reduced by 50%, ART (assisted reproductive technology) live birth rates could increase by 2.67 times, directly demonstrating that medical insurance payment policies significantly influence a country's assisted reproduction penetration rates. In the context of a fertility-friendly atmosphere and reproductive health philosophies, Guangdong, being part of a developed economic region, is more receptive to the adoption of new medical technologies and new treatment methods. With a favorable external environment, JXR is also rapidly iterating on technology. According to Dr. Diao Lianghui, director of the Clinical Research Center for Reproductive Medicine at Shenzhen Zhongshan Maternity and Child Health Hospital, the hospital has a history of 40 years and established the first reproductive medicine center in Shenzhen in 1997, giving birth to Shenzhens first test-tube baby, enjoying significant first-mover advantages and deep clinical experience. As the technical origin of reproductive medicine in the Greater Bay Area, Shenzhen Zhongshan Maternity and Child Health Hospital has always been built on the "Zhongshan Medical Gene", forming a three-dimensional driven system of "professional talent teams + globally leading laboratories + innovative research platforms". Dr. Diao Lianghui stated: "The hospitals innovation advantage lies in the 'clinically-driven problem-solving medical research transformation system'proposing research topics based on clinical issues, supported by research platforms, and transforming technology into practice. Currently, the hospital has established a multi-level research platform encompassing research institutes, key laboratories at provincial and municipal levels, and clinical research centers, forming mature technology transformation paths in key areas such as reproductive immunity, embryo development, and male infertility." He shared that the hospital pioneered the countrys first digital evaluation system for endometrial immune cells, accumulating over 10,000 clinical sample analyses, providing strong support for precise diagnosis and treatment of difficult diseases like recurrent miscarriage. Furthermore, AI microfluidic sperm screening technology in andrology has entered the clinical trial stage, and work for IVD certification is in progress. It was noted that in 1986, invited by the Shenzhen Special Economic Zone government, a medical expert team led by Professor Mei Hua from Sun Yat-sen University First Affiliated Hospital established the Sun Yat-sen University Shenzhen Medical Center in Shenzhen, which was later renamed Sun Yat-sen University Shenzhen Urology Hospital; the same year, Professor Zhuang Guanglun, the "father of China's test-tube babies" from Sun Yat-sen University, established Shenzhens first test-tube baby center at this hospital. In 2004, it was renamed Shenzhen Zhongshan Urology Hospital and gradually developed into a specialty hospital with a focus on assisted reproduction. In 2023, it was officially renamed Shenzhen Zhongshan Maternity and Child Health Hospital, consistently ranking first in Shenzhen in reproductive scale, with nearly 50,000 births resulting from test-tube procedures. To continuously enhance its research and clinical capabilities, Shenzhen Zhongshan Maternity and Child Health Hospital has also been actively recruiting "high-quality" medical talent. For example, after the new campus began operations, several renowned industry experts and physicians, such as Lingnan Famous Doctor Li Baoxing, who previously served as deputy director of the Urology Research Institute at Shenzhen University, and well-known reproductive physician Tian Fuying, have joined. In terms of high-end talent reserves, Shenzhen Zhongshan Maternity and Child Health Hospital currently has eight full-time principal investigators and over 20 core research personnel, collaborating with domestic and international universities for interdisciplinary research. With the continuous advancement of assisted reproductive technology, clinical diagnosis and treatment is evolving towards precision and individuality. Against this backdrop, support from JXR is also indispensable for the comprehensive establishment of a super assisted reproductive medical hub in the Greater Bay Area. It has been reported that in recent years, JXR has been continuously promoting technological innovation across critical links, including data-driven decision-making, oocyte maturation and fertility preservation technologies, male reproductive testing technologies, embryo evaluation and genetic screening technologies, and clinical diagnosis and treatment plans. Moreover, by applying cutting-edge technologies like CAPA-IVM, AI embryo evaluation, non-invasive embryo chromosomal screening, and innovative clinical treatment plans such as the 3F-friendly test-tube baby program, JXR has maintained consistently high assisted reproductive success rates across multiple centers and developed considerable technical advantages in laboratory management and clinical diagnosis and treatment systems. Dr. Diao Lianghui stated: "In recent years, JXR and Shenzhen Zhongshan Maternity and Child Health Hospital have engaged in innovative resource sharing and deep technical cooperation across various dimensions including infrastructure and platform upgrades, introduction of expert resources, and GCP base collaboration and AI network construction." Establishing an assisted reproductive service hub and constructing a protective moat around service and technology. In recent years, with the continuous growth in market demand and increased attention from capital markets, the assisted reproductive industry has entered a new phase of development dividends. For JXR, propelled by multidimensional advancements in clinical technology, service capabilities, and international layout, a relatively complete competitive advantage system has emerged in the Greater Bay Area, solidifying its market position as a leading institution within Chinas assisted reproductive industry. Following the establishment of its southern headquarters, leveraging its cross-regional operational network and scaled business foundation, Jinxin and Shenzhen Zhongshan Maternity and Child Health Hospital are accelerating their construction as a super assisted reproductive medical hub that serves the Greater Bay Area and radiates to Southeast Asia and international markets. In recent years, the trend in Chinas assisted reproductive industry is shifting from limited licenses to scaled operations. In this context, Huang Chunyu, president of Shenzhen Zhongshan Maternity and Child Health Hospital, stated in an interview that the current most scarce resource in the industry is not the license but large assisted reproductive centers capable of scaled and integrated operations. To become a super assisted reproductive medical hub in the Greater Bay Area, brand effect and service breadth are indispensable. Huang Chunyu remarked, "In line with the current industry development trend, Shenzhen Zhongshan Maternity and Child Health Hospital has defined a differentiated competitive strategy: the hospital will strive to break through licensing barriers, focus on technological depth and service breadth, and completely integrate the strategic path of 'deepening technology, broadening regions, lengthening cycles, and strengthening operations'." The official operation of the new campus this year is regarded as a core opportunity for the Shenzhen Zhongshan Maternity and Child Health Hospital's development over the next five years and a key support for executing the strategic path. It is noted that the new campus has achieved a fourfold expansion of usable area compared to the old site, making it the largest private obstetrics and gynecology specialist hospital in the Guangdong-Hong Kong-Macao Greater Bay Area focusing on assisted reproductive medicine. Unlike comprehensive hospitals, it can focus 100% on the fields of obstetrics, gynecology, and reproduction, allowing for more concentrated resource allocation. Huang Chunyu explained that leveraging the upgrade in hardware space, the new campus of Shenzhen Zhongshan Maternity and Child Health Hospital, centered on "one-stop service and integrated medical care", has restructured and deeply integrated six core departments: Reproductive Medicine, Reproductive Urology, Gynecology, Obstetrics, and Reproductive Immunology, along with Traditional Chinese Medicine, and is gradually establishing a full-cycle customer service system covering consultation, treatment, and follow-up management through a digital platform. Additionally, the new campus has significantly optimized patient flow with systems for AI-assisted maternal and child care, personalized patient management, and integrated IVF pregnancy management, constructing a full lifecycle service loop covering "pre-conception, conception, pregnancy, delivery, and postpartum", addressing pain points the old campus could not meet for high-end needs, continuously enhancing patient visit efficiency and treatment experience, thereby establishing differentiated advantages in scaled operations and patient service capabilities, and significantly expanding the hospitals service breadth. Recently, JXR announced its results for the six months ending June 30, 2026, reporting revenues of 1.373 billion yuan, a year-on-year increase of 6.6%; adjusted EBITDA was 340 million yuan, a year-on-year increase of 49.8%. Notably, on the business front, JXR's Shenzhen campus has seen significant results since the second quarter of 2026 due to the 40 years of accumulated medical technology and the new campus hardware upgrades: in the first half of 2026, new patient consultations for infertility surged by 32.5%, the VIP penetration rate increased by 6.9 percentage points to 9.2%, and initial consultations from Hong Kong patients grew by 62% year-on-year. In the future, leveraging the location advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, the company will focus on enhancing VIP and international business, with expectations for rapid growth in its high-net-worth business. In recent years, the state and society have continually improved the fertility support policy system, with assisted reproductive technology gradually evolving from a "supplementary medical service" to a significant component of the "fertility support system", becoming a vital support for building a fertility-friendly society. Against this backdrop, JXR is poised to further strengthen its resource integration and regional collaboration in the Greater Bay Area by establishing a super fertility center centered around Shenzhen Zhongshan Maternity and Child Health Hospital, enhancing the company's integrated assisted reproductive services and women's lifecycle service capacity, thereby consolidating its market position among the leading institutions in the assisted reproductive industry in the Greater Bay Area and nationwide.